4162.TWO

PharmaEngine, Inc. [4162.TWO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

4162.TWO Stock Summary

Top 10 Correlated ETFs

4162.TWO

Top 10 Correlated Stocks

4162.TWO

In the News

4162.TWO Financial details

Company Rating
-
Market Cap
13.95B
Income
274.65M
Revenue
767.67M
Book val./share
-
Cash/share
-
Dividend
2
Dividend %
1.96%
Employees
17
Optionable
No
Shortable
Yes
Earnings
25 Apr 2024
P/E
50.58
Forward P/E
-
PEG
-36.22
P/S
19.83
P/B
3.85
P/C
-
P/FCF
67.4
Quick Ratio
56.93
Current Ratio
61.92
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
1.91
EPS next Y
-
EPS next Q
-
EPS this Y
-13.96%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
45.79%
Revenue last 5Y
19.57%
Revenue Q/Q
-23.83%
EPS Q/Q
-53.57%
-
-
-
-
SMA20
-13.37%
SMA50
-22.44%
SMA100
-6.88%
Inst Own
-
Inst Trans
-
ROA
7%
ROE
8%
ROC
0.09%
Gross Margin
93%
Oper. Margin
46%
Profit Margin
39%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
79.8-122.5
52W High
-26.56%
52W Low
+13.42%
RSI
45.64
Rel Volume
0.51
Avg Volume
1.53M
Volume
772.18K
Perf Week
4.8%
Perf Month
-15.87%
Perf Quarter
-12.16%
Perf Half Y
-12.16%
-
-
-
-
Beta
0.717
-
-
Volatility
1.31%, 8.21%
Prev Close
0.45%
Price
89.6
Change
-2.18%

4162.TWO Financial Performance

4162.TWO Dividend History

4162.TWO Frequently Asked Questions

What is PharmaEngine, Inc. stock symbol ?

PharmaEngine, Inc. is a TW stock and trading under the symbol 4162.TWO

What is PharmaEngine, Inc. stock quote today ?

PharmaEngine, Inc. stock price is $89.6 today.

Is PharmaEngine, Inc. stock public?

Yes, PharmaEngine, Inc. is a publicly traded company.

Something similar

Top by Market Cap
TSLA
MSFT
NVDA
EMBASSY.NS
AMZN
Top Correlated ETFs
ROBG.L
IQCY.L
AMEC.DE
W1TA.DE
AMAP.L
Top Correlated Stocks
3059.TW
3545.TW
6531.TW
3031.TW
3138.TW
Similar Market Cap
600820.SS
ROKU
0RT6.L
4092.T
1321.TW

Company Profile

Healthcare Biotechnology
  • Volume Average 1.53M
  • Market Capitalization 13.95B
  • Employee 17
  • CEO Mr. Hong-Ren Wang Ph.D.
  • Headquarters Taipei,TW
  • IPO Date 2012-06-20
  • Website https://www.pharmaengine.com

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It is developing ONIVYDE, a proprietary liposome encapsulation of irinotecan, a topoisomerase 1 inhibitor for the treatment of metastatic pancreatic cancer; PEP06, which is in Phase I clinical trial for the treatment of cancer; and PEP07, a Chk1 inhibitor, which is in preclinical development stage to accumulate DNA damage in cells, lead to replication catastrophe, and induce cell apoptosis. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.